The clinical impact of fluoroquinolone resistance in patients with E coli bacteremia

Journal of Hospital Medicine

Volumn 6, Issue 6, 2011, Pages 344-349

  Camins, Bernard C ^a   Marschall, Jonas ^a   De Vader, Shannon R ^a   Maker, Dawn E ^a   Hoffman, Matthew W ^a   Fraser, Victoria J ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; PROBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; BLOODSTREAM INFECTION; CASE CONTROL STUDY; CHARLSON COMORBIDITY SCORE; COMORBIDITY; CONTROLLED STUDY; CORTICOSTEROID THERAPY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; HEALTH CARE FACILITY; HEART DISEASE; HOSPITAL; HOSPITAL ADMISSION; HOSPITAL INFECTION; HUMAN; KIDNEY DYSFUNCTION; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SCORING SYSTEM; UNIVERSITY HOSPITAL;

ACADEMIC MEDICAL CENTERS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; FLUOROQUINOLONES; HOSPITAL MORTALITY; HUMANS; MALE; MISSOURI; RETROSPECTIVE STUDIES;

EID: 80051566218     PISSN: 15535592     EISSN: 15535606     Source Type: Journal    
DOI: 10.1002/jhm.877     Document Type: Article

References (23)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005; 41: 848-854.
2. Diekema DJ, Pfaller MA, Jones RN, et al. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin Infect Dis. 1999; 29: 595-607.
3. Kern WV, Andriof E, Oethinger M, Kern P, Hacker J, Marre R. Emergence of fluoroquinolone-resistant Escherichia coli at a cancer center. Antimicrob Agents Chemother. 1994; 38: 681-687.
4. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis. 1995; 20: 557-560; discussion 561-563.
5. Oteo J, Lazaro E, de Abajo FJ, Baquero F, Campos J. Antimicrobial-resistant invasive Escherichia coli, Spain. Emerg Infect Dis. 2005; 11: 546-553.
6. Garau J, Xercavins M, Rodriguez-Carballeira M, et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother. 1999; 43: 2736-2741.
7. Huotari K, Tarkka E, Valtonen V, Kolho E. Incidence and risk factors for nosocomial infections caused by fluoroquinolone-resistant Escherichia coli. Eur J Clin Microbiol Infect Dis. 2003; 22: 492-495.
8. Lautenbach E, Fishman NO, Bilker WB, et al. Risk factors for fluoroquinolone resistance in nosocomial Escherichia coli and Klebsiella pneumoniae infections. Arch Intern Med. 2002; 162: 2469-2477.
9. Ortega M, Marco F, Soriano A, et al. Analysis of 4758 Escherichia coli bacteraemia episodes: predictive factors for isolation of an antibiotic-resistant strain and their impact on the outcome. J Antimicrob Chemother. 2009; 63: 568-574.
10. Pena C, Albareda JM, Pallares R, Pujol M, Tubau F, Ariza J. Relationship between quinolone use and emergence of ciprofloxacin-resistant Escherichia coli in bloodstream infections. Antimicrob Agents Chemother. 1995; 39: 520-524.
11. Laupland KB, Gregson DB, Church DL, Ross T, Pitout JD. Incidence, risk factors and outcomes of Escherichia coli bloodstream infections in a large Canadian region. Clin Microbiol Infect. 2008; 14: 1041-1047.
12. Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC. Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis. 2001; 33: 48-53.
13. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis. 2005; 41: 923-929.
14. Killgore KM, March KL, Guglielmo BJ. Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection. Ann Pharmacother. Jul- 2004; 38: 1148-1152.
15. Peralta G, Sanchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother. 2007; 60: 855-863.
16. Drews SJ, Poutanen SM, Mazzulli T, et al. Decreased prevalence of virulence factors among ciprofloxacin-resistant uropathogenic Escherichia coli isolates. J Clin Microbiol. 2005; 43: 4218-4220.
17. Vila J, Simon K, Ruiz J, et al. Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis. 2002; 186: 1039-1042.
18. Takahashi A, Muratani T, Yasuda M, et al. Genetic profiles of fluoroquinolone-resistant Escherichia coli isolates obtained from patients with cystitis: phylogeny, virulence factors, PAIusp subtypes, and mutation patterns. J Clin Microbiol. 2009; 47: 791-795.
19. Moreno E, Planells I, Prats G, Planes AM, Moreno G, Andreu A. Comparative study of Escherichia coli virulence determinants in strains causing urinary tract bacteremia versus strains causing pyelonephritis and other sources of bacteremia. Diagn Microbiol Infect Dis. 2005; 53: 93-99.
20. Bonacorsi S, Houdouin V, Mariani-Kurkdjian P, Mahjoub-Messai F, Bingen E. Comparative prevalence of virulence factors in Escherichia coli causing urinary tract infection in male infants with and without bacteremia. J Clin Microbiol. 2006; 44: 1156-1158.
21. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA). Clin Infect Dis. 1999; 29: 745-758.
22. Parsi MA, Atreja A, Zein NN. Spontaneous bacterial peritonitis: recent data on incidence and treatment. Cleve Clin J Med. 2004; 71: 569-576.
23. Rimola A, Garcia-Tsao G, Navasa M, et al. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000; 32: 142-153.